--- title: "Partnering with Eli Lilly to promote the localization of oral GLP-1 drug production! Pharmaron's stock price surged" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/278816827.md" description: "Pharmaron's stock price surged due to a $200 million investment partnership with Eli Lilly, focusing on the localized production of oral GLP-1 drugs. H shares rose by 13.23% at one point, while A shares increased by 5.82%. Eli Lilly plans to invest $3 billion over the next decade to expand its supply chain in China and enhance the production capacity of the oral small molecule GLP-1 receptor agonist Orforglipron to meet the demand in the Chinese market" datetime: "2026-03-12T03:53:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278816827.md) - [en](https://longbridge.com/en/news/278816827.md) - [zh-HK](https://longbridge.com/zh-HK/news/278816827.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278816827.md) | [English](https://longbridge.com/en/news/278816827.md) # Partnering with Eli Lilly to promote the localization of oral GLP-1 drug production! Pharmaron's stock price surged On March 12, the leading company in the CXO industry, Pharmaron (300759.SZ) (03759.HK), experienced a significant surge in its stock price. Its H shares rose by as much as 13.23% during the trading session, and as of the time of writing, the increase was 7.53%, priced at HKD 20.00 per share; its A shares also performed well, with an increase of 5.82%, priced at RMB 28.75 per share. **From the news perspective, the substantial movement in the stock today is attributed to a major announcement—collaboration with Eli Lilly, securing a USD 200 million investment, focusing on the localized production of oral weight loss drugs, injecting optimistic expectations into the market.** On March 11, Pharmaron's official WeChat account announced that the company had reached a production cooperation agreement with Eli Lilly regarding the first registered oral small molecule GLP-1 (glucagon-like peptide-1) receptor agonist, Orforglipron. According to the agreement, Eli Lilly is expected to invest USD 200 million in Pharmaron and support its technological capability development, with plans to further expand the cooperation scale based on future developments. **This collaboration is a key initiative in Eli Lilly's supply chain strategy upgrade in China.** On the same day, **Eli Lilly's official account announced plans to invest a total of USD 3 billion over the next decade to comprehensively expand its supply chain capacity in China, establishing a local production and supply system for oral solid formulations, focusing on the production capacity of the first registered oral small molecule GLP-1 receptor agonist, Orforglipron. Eli Lilly plans to collaborate with multiple local partners to plan and layout large-scale production capacity for future pipelines, including Orforglipron.** Eli Lilly stated that this investment is expected to significantly enhance supply, meeting the medication needs of Chinese patients while also creating value for local industry development, economic growth, and employment. According to data, Orforglipron is Eli Lilly's first registered oral small molecule GLP-1 receptor agonist, and Eli Lilly China has submitted its application for marketing approval to the National Medical Products Administration for the treatment of type 2 diabetes and obesity by the end of 2025. Data from the "World Obesity Map 2025" indicates that the overweight/obesity rate among Chinese adults has exceeded 50%. The enormous unmet clinical demand presents a vast market space for GLP-1 drugs. Some analysts pointed out that Pharmaron's collaboration with Eli Lilly for the commercial production of formulations is not only an important milestone for the company's CDMO business but is also expected to directly translate into performance growth. Morgan Stanley's research report indicated that Pharmaron has secured a major commercial production contract from Eli Lilly, involving the production of Orforglipron formulations in China. Eli Lilly has committed to investing USD 3 billion in China over the next decade, with USD 200 million already earmarked for Pharmaron's capacity building, and there is potential for further expansion. The firm believes that the contract is likely to accelerate Pharmaron's profit growth in 2026 to 2027, with management expecting a profit growth of about 10% in 2025. The stock is currently trading at a forecasted price-to-earnings ratio of 14 times for 2026, and Pharmaron's H shares are currently valued below its peers (over 20 times) It is also worth mentioning that at the 2025 Hong Kong Wealth Management Summit and the "Top 100 Hong Kong Stocks" award ceremony held at the beginning of the year, Pharmaron won two awards: "Outstanding Hong Kong Stock Connect Company of the Year" and "Innovative Pioneer in Medicine and Healthcare of the Year," which confirms its technological accumulation and market competitiveness in the field of innovative drug research and development services ### 相關股票 - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-HK/quote/159570.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/zh-HK/quote/520500.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [PHARMARON (03759.HK)](https://longbridge.com/zh-HK/quote/03759.HK.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [Pharmaron (300759.CN)](https://longbridge.com/zh-HK/quote/300759.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/zh-HK/quote/562050.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) ## 相關資訊與研究 - [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md) - [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-HK/news/281501537.md) - [08:33 ETDrugwatch Investigation Reveals Big Pharma Profits Continue to Outpace Billions in Legal Penalties](https://longbridge.com/zh-HK/news/281368752.md) - [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/zh-HK/news/281103720.md) - [Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout](https://longbridge.com/zh-HK/news/281635912.md)